Biomerica Inc Stock Price, News & Analysis

Biomerica (Nasdaq: BMRA) reported first quarter fiscal 2026 results for the period ended August 31, 2025. Net sales were $1.4M versus $1.8M a year earlier, while gross margin rose to 31% from 16% driven by a higher‑margin product mix and contract manufacturing contribution. Operating expenses fell to $1.5M from $1.7M, producing an improved operating loss of $1.1M versus $1.4M. A non‑recurring tax credit produced a small net profit of about $2,000 versus a $1.3M loss prior year. Key commercial and regulatory updates include a PLA code for inFoods® IBS and UAE approvals for Fortel® Ulcer and Fortel® Kidney home tests, plus launch of an AI inFoods® IBS Trigger Food Navigator.

Biomerica (NASDAQ: BMRA) announced that Gary Huff was appointed to its Board of Directors as an independent director effective October 8, 2025. Mr. Huff brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, commercial launches, and sales growth, including prior service as Chief Executive Officer of LabCorp Diagnostics.

The company said Huff operates an advisory firm, sits on the boards of Lighthouse Labs and Tribal Diagnostics, and has advised health systems and firms such as McKinsey and Cerberus. Biomerica highlighted his experience as relevant to advancing its diagnostic portfolio, including the inFoods® IBS product.

Biomerica (Nasdaq: BMRA) has launched the inFoods® IBS Trigger Food Navigator, an AI-powered digital tool designed to enhance their existing IBS diagnostic solution. The Navigator helps patients better manage their IBS symptoms by providing smart meal suggestions and ingredient substitutions based on their personalized trigger food profile.

The company's clinical studies showed significant results, with 59.6% of treatment group patients achieving FDA's endpoint for abdominal pain reduction compared to 42.2% in the control group. Even higher success rates were observed in IBS-C (67.1%) and IBS-M (66.0%) patients.

Developed with University of Michigan dietitians, the Navigator includes features like smart food identification, AI-driven meal suggestions, and an alternative food database. The tool is provided at no additional cost to existing inFoods® IBS test customers and is available through healthcare providers or online for new patients.

Biomerica (NASDAQ:BMRA) has received approval from the UAE Ministry of Health and Prevention for its Fortel® Kidney Test for home use. The 10-minute diagnostic test detects early kidney damage by identifying low albumin levels in urine, particularly targeting patients with diabetes and hypertension.

The approval addresses a significant market, as approximately 25% of UAE nationals have diabetes, while hypertension affects 31% of adults in the region. The test will be distributed through pharmacies, clinics, and hospitals throughout the UAE, expanding Biomerica's presence in the Middle East following the success of its EZ Detect™ Colon Disease Test.

Biomerica (NASDAQ: BMRA) reported its fiscal year 2025 results, showing a 19% improvement in operating loss to $5.1 million despite slight revenue decline. The company achieved $5.3 million in revenue, down from $5.4 million in the previous year, with gross profit at $498,000.

Key achievements include $1.3 million in operating expense reductions and improved cash management, with cash used in operations decreasing to $3.8 million from $5.3 million. Strategic milestones include receiving a PLA code for inFoods® IBS test, expanding in the MENA region, and launching direct-to-consumer availability of inFoods® IBS with a new patient self-collection system.

The company secured EU IVDR certification for food-intolerance diagnostic tests and obtained three new international patents for its inFoods® technology platform applications in various gastrointestinal conditions.

Biomerica (Nasdaq: BMRA) has received approval from the UAE Ministry of Health and Prevention for its Fortel® Ulcer Test for home use. This 10-minute diagnostic test detects antibodies to Helicobacter pylori (H. pylori), a bacterium affecting 41% of the UAE population and linked to approximately 80% of gastric cancer cases.

The test will be distributed through UAE-based partners and made available at pharmacies, clinics, and online platforms. H. pylori, classified as a Class 1 carcinogen by WHO, can lead to serious complications in up to 20% of infected individuals if untreated, including peptic ulcers and gastric cancer. This approval strengthens Biomerica's presence in the Middle East market, following their successful launch of the EZ Detect™ Colon Disease Test.

Biomerica (NASDAQ: BMRA) has achieved a significant milestone as its inFoods® IBS test received a CPT® Proprietary Laboratory Analysis (PLA) code from the American Medical Association CPT editorial panel. The code, effective October 1, 2025, enables insurance claims submission to Medicare and private insurers.

The inFoods® IBS test is a pioneering diagnostic tool that identifies patient-specific food triggers for IBS symptoms. Clinical trial results published in Gastroenterology demonstrated significant symptom reduction in patients following test-based dietary recommendations. The test addresses a substantial market, as IBS affects 10-15% of U.S. adults with $10 billion in direct annual medical costs.

Biomerica (NASDAQ: BMRA) has appointed Scott Madel as Chief Commercial Officer to accelerate the commercialization of inFoods® IBS. Madel brings over 20 years of experience in healthcare and diagnostics, most recently serving as President of Boston Heart Diagnostics. His track record includes leading successful organizational turnarounds and growing Genova Diagnostics to over $100 million in annual revenue.

In his new role, Madel will focus on strategic partnerships, payer strategy, achieving 3rd party reimbursement, and expanding provider engagement for inFoods® IBS. His appointment aims to drive revenue growth and market expansion for Biomerica's innovative gastroenterology solutions.

Biomerica (NASDAQ: BMRA) has appointed Eric B. Chin to its Board of Directors effective June 4, 2025. Chin, who currently serves as CFO of Akido Labs where he helped raise $60M in recent financing, will chair the Audit Committee and serve on the Nominating and Corporate Governance Committee and Compensation Committee. With over 20 years of financial experience in healthcare, Chin has held executive positions at Astrana Health, Public Storage, and Alexandria Real Estate Equities. He is also a board member, Treasurer, and Secretary of Rhode Island Primary Care Physicians Corporation. Chin replaces Ms. Cathy Coste, who stepped down without any disagreements regarding company operations, policies, or practices.